These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

291 related items for PubMed ID: 22415852

  • 1. Celecoxib inhibits growth of human autosomal dominant polycystic kidney cyst-lining epithelial cells through the VEGF/Raf/MAPK/ERK signaling pathway.
    Xu T, Wang NS, Fu LL, Ye CY, Yu SQ, Mei CL.
    Mol Biol Rep; 2012 Jul; 39(7):7743-53. PubMed ID: 22415852
    [Abstract] [Full Text] [Related]

  • 2. The Raf kinase inhibitor PLX5568 slows cyst proliferation in rat polycystic kidney disease but promotes renal and hepatic fibrosis.
    Buchholz B, Klanke B, Schley G, Bollag G, Tsai J, Kroening S, Yoshihara D, Wallace DP, Kraenzlin B, Gretz N, Hirth P, Eckardt KU, Bernhardt WM.
    Nephrol Dial Transplant; 2011 Nov; 26(11):3458-65. PubMed ID: 21804086
    [Abstract] [Full Text] [Related]

  • 3. Rosiglitazone inhibits transforming growth factor-β1 mediated fibrogenesis in ADPKD cyst-lining epithelial cells.
    Liu Y, Dai B, Xu C, Fu L, Hua Z, Mei C.
    PLoS One; 2011 Nov; 6(12):e28915. PubMed ID: 22174924
    [Abstract] [Full Text] [Related]

  • 4. Steviol retards renal cyst growth through reduction of CFTR expression and inhibition of epithelial cell proliferation in a mouse model of polycystic kidney disease.
    Yuajit C, Muanprasat C, Gallagher AR, Fedeles SV, Kittayaruksakul S, Homvisasevongsa S, Somlo S, Chatsudthipong V.
    Biochem Pharmacol; 2014 Apr 01; 88(3):412-21. PubMed ID: 24518257
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A new in vitro bioassay for cyst formation by renal cells from an autosomal dominant rat model of polycystic kidney disease.
    Pey R, Bach J, Schieren G, Gretz N, Hafner M.
    In Vitro Cell Dev Biol Anim; 1999 Apr 01; 35(10):571-9. PubMed ID: 10614866
    [Abstract] [Full Text] [Related]

  • 8. VEGF receptor inhibition blocks liver cyst growth in pkd2(WS25/-) mice.
    Amura CR, Brodsky KS, Groff R, Gattone VH, Voelkel NF, Doctor RB.
    Am J Physiol Cell Physiol; 2007 Jul 01; 293(1):C419-28. PubMed ID: 17475663
    [Abstract] [Full Text] [Related]

  • 9. Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys.
    Yamaguchi T, Nagao S, Wallace DP, Belibi FA, Cowley BD, Pelling JC, Grantham JJ.
    Kidney Int; 2003 Jun 01; 63(6):1983-94. PubMed ID: 12753285
    [Abstract] [Full Text] [Related]

  • 10. Rosiglitazone inhibits cell proliferation by inducing G1 cell cycle arrest and apoptosis in ADPKD cyst-lining epithelia cells.
    Liu Y, Dai B, Fu L, Jia J, Mei C.
    Basic Clin Pharmacol Toxicol; 2010 Jun 01; 106(6):523-30. PubMed ID: 20210794
    [Abstract] [Full Text] [Related]

  • 11. Combined cetuximab and celecoxib treatment exhibits a synergistic anticancer effect on human oral squamous cell carcinoma in vitro and in vivo.
    Qian M, Qian D, Jing H, Li Y, Ma C, Zhou Y.
    Oncol Rep; 2014 Oct 01; 32(4):1681-8. PubMed ID: 25328959
    [Abstract] [Full Text] [Related]

  • 12. Calcium restores a normal proliferation phenotype in human polycystic kidney disease epithelial cells.
    Yamaguchi T, Hempson SJ, Reif GA, Hedge AM, Wallace DP.
    J Am Soc Nephrol; 2006 Jan 01; 17(1):178-87. PubMed ID: 16319189
    [Abstract] [Full Text] [Related]

  • 13. Sorafenib inhibits cAMP-dependent ERK activation, cell proliferation, and in vitro cyst growth of human ADPKD cyst epithelial cells.
    Yamaguchi T, Reif GA, Calvet JP, Wallace DP.
    Am J Physiol Renal Physiol; 2010 Nov 01; 299(5):F944-51. PubMed ID: 20810616
    [Abstract] [Full Text] [Related]

  • 14. The lonidamine derivative H2-gamendazole reduces cyst formation in polycystic kidney disease.
    Sundar SV, Zhou JX, Magenheimer BS, Reif GA, Wallace DP, Georg GI, Jakkaraj SR, Tash JS, Yu ASL, Li X, Calvet JP.
    Am J Physiol Renal Physiol; 2022 Oct 01; 323(4):F492-F506. PubMed ID: 35979967
    [Abstract] [Full Text] [Related]

  • 15. Mitochondrial Abnormality Facilitates Cyst Formation in Autosomal Dominant Polycystic Kidney Disease.
    Ishimoto Y, Inagi R, Yoshihara D, Kugita M, Nagao S, Shimizu A, Takeda N, Wake M, Honda K, Zhou J, Nangaku M.
    Mol Cell Biol; 2017 Dec 15; 37(24):. PubMed ID: 28993480
    [Abstract] [Full Text] [Related]

  • 16. Lansoprazole reduces renal cyst in polycystic kidney disease via inhibition of cell proliferation and fluid secretion.
    Nantavishit J, Chatsudthipong V, Soodvilai S.
    Biochem Pharmacol; 2018 Aug 15; 154():175-182. PubMed ID: 29746821
    [Abstract] [Full Text] [Related]

  • 17. Targeting of sodium-glucose cotransporters with phlorizin inhibits polycystic kidney disease progression in Han:SPRD rats.
    Wang X, Zhang S, Liu Y, Spichtig D, Kapoor S, Koepsell H, Mohebbi N, Segerer S, Serra AL, Rodriguez D, Devuyst O, Mei C, Wüthrich RP.
    Kidney Int; 2013 Nov 15; 84(5):962-8. PubMed ID: 23715121
    [Abstract] [Full Text] [Related]

  • 18. The tyrosine-kinase inhibitor Nintedanib ameliorates autosomal-dominant polycystic kidney disease.
    Jamadar A, Suma SM, Mathew S, Fields TA, Wallace DP, Calvet JP, Rao R.
    Cell Death Dis; 2021 Oct 14; 12(10):947. PubMed ID: 34650051
    [Abstract] [Full Text] [Related]

  • 19. Proliferative signaling by ERBB proteins and RAF/MEK/ERK effectors in polycystic kidney disease.
    Parker MI, Nikonova AS, Sun D, Golemis EA.
    Cell Signal; 2020 Mar 14; 67():109497. PubMed ID: 31830556
    [Abstract] [Full Text] [Related]

  • 20. Pharmacological Effects of Panduratin A on Renal Cyst Development in In Vitro and In Vivo Models of Polycystic Kidney Disease.
    Tonum K, Srimai N, Chabang N, Fongsupa S, Tuchinda P, Torres JA, Weimbs T, Soodvilai S.
    Int J Mol Sci; 2022 Apr 14; 23(8):. PubMed ID: 35457146
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.